Parent Project Muscular Dystrophy’s AVI webinar covers a pre-data update on AVI BioPharma’s Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping. The webinar was lead by Chris Garabedian, the CEO of AVI BioPharma.
by: Parent Project Muscular Dystrophy
